Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Powles, T. B.
Chistyakov, V.
Beliakouski, V.
Semenov, A.
Everaert, E.
Baranau, Y.
Moreno, V.
Valderrama, B. Perez
Vano, Y.
Del Conte, G.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
